Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety, tolerability and PK of single ascending doses of ALN-AGT01 RVR.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ALN-AGT01 RVR | Experimental | Participants will be administered a single dose of ALN-AGT01 RVR. |
|
| Placebo | Placebo Comparator | Participants will be administered a single dose of placebo. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ALN-AGT01 RVR | Drug | ALN-AGT01 RVR will be administered subcutaneously (SC) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of Adverse Events (AEs) | Up to 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Plasma Concentration-time Curve (AUC) of ALN-AGT01 RVR in Plasma | Predose and up to 3 days postdose | |
| Maximum Observed Plasma Concentration (Cmax) of ALN-AGT01 RVR in Plasma | Predose and up to 3 days postdose |
Not provided
Inclusion Criteria
Exclusion Criteria
Note: other protocol defined inclusion / exclusion criteria apply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Trial Site | Montreal | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Placebo will be administered SC |
|
| Time to Maximum Plasma Concentration (Tmax) of ALN-AGT01 RVR in Plasma | Predose and up to 3 days postdose |
| Concentrations of ALN-AGT01 RVR in Urine | Fraction of ALN-AGT01 RVR excreted in urine | Predose and up to 1 day postdone |